Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8PM8

V30M Transthyretin structure in complex with Tolcalpone

8PM8 の概要
エントリーDOI10.2210/pdb8pm8/pdb
分子名称Transthyretin, Tolcapone (3 entities in total)
機能のキーワードaggregation, inhibitor, amyloid, transport protein
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数2
化学式量合計28165.33
構造登録者
Varejao, N.,Pinheiro, F.,Pallares, I.,Ventura, S.,Reverter, D. (登録日: 2023-06-28, 公開日: 2024-05-08)
主引用文献Pinheiro, F.,Varejao, N.,Sanchez-Morales, A.,Bezerra, F.,Navarro, S.,Velazquez-Campoy, A.,Busque, F.,Almeida, M.R.,Alibes, R.,Reverter, D.,Pallares, I.,Ventura, S.
PITB: A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties.
Eur.J.Med.Chem., 261:115837-115837, 2023
Cited by
PubMed Abstract: The aggregation of wild-type transthyretin (TTR) and over 130 genetic TTR variants underlies a group of lethal disorders named TTR amyloidosis (ATTR). TTR chemical chaperones are molecules that hold great promise to modify the course of ATTR progression. In previous studies, we combined rational design and molecular dynamics simulations to generate a series of TTR selective kinetic stabilizers displaying exceptionally high affinities. In an effort to endorse the previously developed molecules with optimal pharmacokinetic properties, we conducted structural design optimization, leading to the development of PITB. PITB binds with high affinity to TTR, effectively inhibiting tetramer dissociation and aggregation of both the wild-type protein and the two most prevalent disease-associated TTR variants. Importantly, PITB selectively binds and stabilizes TTR in plasma, outperforming tolcapone, a drug currently undergoing clinical trials for ATTR. Pharmacokinetic studies conducted on mice confirmed that PITB exhibits encouraging pharmacokinetic properties, as originally intended. Furthermore, PITB demonstrates excellent oral bioavailability and lack of toxicity. These combined attributes position PITB as a lead compound for future clinical trials as a disease-modifying therapy for ATTR.
PubMed: 37837673
DOI: 10.1016/j.ejmech.2023.115837
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.57 Å)
構造検証レポート
Validation report summary of 8pm8
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon